NCT00411996View on ClinicalTrials.gov

The Pharmacokinetics and Safety of IDV/r With NRTIs in HIV/TB Co-infected Patients Receiving Rifampicin

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

October 31, 2008

Study Completion Date

December 31, 2009

Conditions
HIV InfectionsTuberculosis
Interventions
DRUG

indinavir/ritonavir

IDV/r 600/100 mg BID + rifampicin OD for at least 2 weeks

Trial Locations (1)

10330

HIV-NAT Thai Red Cross AIDS Research Center, Bangkok

All Listed Sponsors
lead

The HIV Netherlands Australia Thailand Research Collaboration

OTHER

NCT00411996 - The Pharmacokinetics and Safety of IDV/r With NRTIs in HIV/TB Co-infected Patients Receiving Rifampicin | Biotech Hunter | Biotech Hunter